Aspyre Clinical Tests provide simple, fast and reliable biomarker testing, ensuring that all patients have access to the best treatment options. With our advanced technology, patients can get access to the right treatment more quickly and more affordably than with other testing methods.
One assay to test all guideline-recommended genes associated with FDA-approved targeted therapies from tissue or blood.
98% of cases processed within 2 days, meaning patients can go from diagnosis to actionable biomarker results in a matter of days, not weeks.
In a recent study, 98% of samples that failed next-generation sequencing (NGS) were rescued by Aspyre.1
Aspyre Clinical Test for Lung simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify DNA mutations and RNA fusions, while avoiding the additional time and expense of running separate assays.
Aspyre Clinical Test for Lung Can be used on either tissue or blood samples with tumor content as low as 10%. Whichever sample you submit, the test simultaneously analyzes DNA and RNA and covers all guideline-recommended genes for non-small cell lung cancer (NSCLC).
Aspyre Clinical Test for Lung is performed at Biofidelity’s CAP-accredited, CLIA-certified laboratory.
Analyzes all 11 guideline-recommended genes for NSCLC
Provides 2-day results in a simple, 2-page report
Simultaneously analyzes DNA & RNA from tissue or blood in a single test
Works with challenging samples and low DNA/RNA input
Specificity
DNA (SNVs & Indels)
Median panel-wide limit of detection 95%
DNA (SNVs & Indels)
Specificity
RNA (Fusions)
Amplifiable copies
Median panel-wide limit of detection 95%
RNA (Fusions)
Specificity
MET Exon 14 Skipping
Amplifiable copies
MET Exon 14 Skipping
Specificity
DNA (SNVs & Indels)
Median panel-wide limit of detection 95%
DNA (SNVs & Indels)
Specificity
RNA (Fusions)
Amplifiable copies
Median panel-wide limit of detection 95%
RNA (Fusions)
Specificity
MET Exon 14 Skipping
Amplifiable copies
MET Exon 14 Skipping
The Aspyre Clinical Test for Lung is a Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by Biofidelity Inc. in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Want to bring Aspyre Lung into your own laboratory for research use? Aspyre Lung Reagents enable fast, simple, reliable detection of established biomarkers for use in NSCLC research.
This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.
This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.
Simple, fast, reliable detection of NSCLC biomarkers from tissue or blood within 2 days.
